Victoza vs. Glipizide

See how Victoza and Glipizide compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Victoza is a once-daily injectable GLP-1 drug that also lowers cardiovascular risk, while glipizide is an inexpensive oral pill that only targets blood sugar.

  • Glipizide carries a real risk of hypoglycemia (low blood sugar), a risk that is much lower with Victoza.

  • Victoza costs far more than glipizide but adds cardiovascular protection and pediatric approval that glipizide does not have.

Victoza vs. Glipizide Drug Summary

Victoza

Victoza (liraglutide) is a GLP-1 receptor agonist used to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with established heart disease. It is given as a once-daily injection under the skin, with the dose increased gradually over the first few weeks.

Glipizide

Glipizide is a sulfonylurea that helps the pancreas release more insulin to lower blood sugar in adults with type 2 diabetes. It comes as an oral tablet, taken once or twice daily depending on the formulation, and has been used since the 1980s. It works alongside diet and exercise to manage glucose levels.

Victoza vs. Glipizide Side Effects

Victoza

Most common
Diarrhea (up to 12%)
Nausea (up to 5%)
Vomiting (up to 5%)
Decreased appetite (up to 5%)

Glipizide

Most common
Diarrhea (up to 1%)
Nausea (up to 1%)
Dizziness (up to 2%)
Drowsiness (up to 2%)

Victoza vs. Glipizide Dosage

Victoza

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 1.8 mg once daily Week 3 onward
Dose changes 2 increases Every week

Glipizide

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once daily At the start
Maximum dose 5-20 mg once daily If needed
Dose changes 5 increases As tolerated

Victoza vs. Glipizide Indications

Victoza

Victoza is FDA-approved as an add-on to diet and exercise for improving blood sugar in adults and children 10 and older with type 2 diabetes. It is also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes and existing heart disease. It is not approved for type 1 diabetes.

  • Adjunct to diet and exercise in adults and children 10+

  • Reduces risk of major cardiovascular events in adults with heart disease

  • Not approved for type 1 diabetes

  • Approved for pediatric type 2 diabetes patients

Glipizide

Glipizide is FDA-approved as an add-on to diet and exercise to control blood sugar in adults with type 2 diabetes. It has no cardiovascular risk-reduction indication and is not approved for type 1 diabetes or diabetic ketoacidosis. It remains one of the most widely prescribed generic oral diabetes medications.

  • Adjunct to diet and exercise in adults with type 2 diabetes

  • Not approved for type 1 diabetes or diabetic ketoacidosis

  • Widely used as a first-line generic oral option

  • Available in immediate-release and extended-release tablets

Victoza vs. Glipizide Pros and Cons

Victoza

Victoza offers glycemic control plus a proven cardiovascular benefit, making it a strong option for patients with type 2 diabetes and heart disease. It requires a daily injection and carries a boxed warning about thyroid tumor risk seen in animal studies. Coverage varies, and the list price is substantially higher than older oral options.

Pros

  • Only needs to be injected once a day, not multiple pills

  • FDA-approved to lower cardiovascular risk in patients with heart disease

  • Approved for use in children as young as 10

  • Low risk of causing dangerous low blood sugar on its own

Cons

  • Carries a boxed warning for thyroid C-cell tumor risk

  • Requires an injection, which some patients dislike

  • Common gastrointestinal side effects like nausea and vomiting

  • Roughly $935 to $1,470 per month without insurance, before savings programs

Glipizide

Glipizide is a low-cost, well-established oral option that has been used for decades to lower blood sugar in type 2 diabetes. It carries a higher risk of hypoglycemia than Victoza and has not been shown to reduce cardiovascular risk. It remains inexpensive and widely available as a generic.

Pros

  • Roughly $10 to $35 per month, one of the least expensive diabetes drugs

  • Long track record of use dating back to 1984

  • Simple oral tablet, no injections needed

  • Widely stocked generic with broad insurance coverage

Cons

  • Higher risk of hypoglycemia, especially in elderly patients

  • Sulfonylureas as a class are linked to increased cardiovascular mortality risk

  • Not proven to reduce cardiovascular events like Victoza is

  • No effect on appetite or weight, unlike GLP-1 drugs

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.